Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two ...
Skyrocketing demand for weight loss and diabetes drugs has forced Eli Lilly and Novo Nordisk, to invest billions to increase ...
Eli Lilly will report third-quarter earnings Wednesday morning. Investor focus remains on the production and sales of its ...
(Reuters) -Eli Lilly missed Wall Street estimates for third-quarter profit on Wednesday, hurt by higher manufacturing costs ...
U.S. stock indexes edged lower Wednesday after drops for Eli Lilly and chip companies overshadowed a jump for Google’s parent ...
Eli Lilly (LLY) expects to start selling its weight-loss drug tirzepatide, branded as Mounjaro, in Hong Kong as early as the ...
GHP Investment Advisors Inc. lifted its stake in Eli Lilly and Company (NYSE:LLY – Free Report) by 5.1% during the third ...